{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:46:26Z","timestamp":1790005586413,"version":"4.0.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa\/foscarbidopa (LDp\/CDp), a 24\u2010hour\/day continuous subcutaneous infusion of levodopa\/carbidopa (LD\/CD) prodrugs, improves motor complications. The feasibility and sustainability of LDp\/CDp monotherapy warrants investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim was to report the efficacy and safety of LDp\/CDp monotherapy and combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis assessed patients with PD and\u2009\u22652.5 \u201cOff\u201d hours\/day receiving LDp\/CDp monotherapy or combination therapy in 3 trials: a 12\u2010week randomized active\u2010controlled trial (RCT) comparing LDp\/CDp with oral immediate\u2010release LD\/CD (NCT04380142), a 52\u2010week open\u2010label trial of LDp\/CDp (NCT03781167), and its 96\u2010week open\u2010label extension study (OLE; NCT04379050). Monotherapy was defined as receiving LDp\/CDp without concomitant PD medications; combination therapy was defined as receiving LDp\/CDp with other PD medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the RCT, 74 of 141 patients received LDp\/CDp. The 52\u2010week trial enrolled 244 patients; 129 entered the OLE. Of LDp\/CDp\u2010treated patients, 19 of 74 (25.7%) in the RCT, 49 of 244 (20.1%) in the 52\u2010week trial, and 46 of 129 (35.7%) in the OLE received monotherapy. In the RCT, mean (standard deviation) change from baseline to week 12 in \u201cOff\u201d time was \u22124.5 (4.4) and\u2009\u22123.0 (3.5) hours for monotherapy and combination therapy, respectively; +4.1 (3.7) and\u2009+3.1 (3.6) hours for \u201cOn\u201d time without troublesome dyskinesia; and\u2009+4.0 (3.6) and\u2009+4.0 (3.9) hours for \u201cOn\u201d time without dyskinesia. Efficacy was similar in open\u2010label trials. Improvements in the Movement Disorder Society\u2010Unified Parkinson's Disease Rating Scale Part II, 39\u2010item Parkinson's Disease Questionnaire, Parkinson's Disease Sleep Scale\u20102 scores, and overall safety were comparable between monotherapy and combination therapy groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LDp\/CDp monotherapy treatment may be suitable for up to 96\u2009weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70245","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:59:12Z","timestamp":1753876752000},"page":"181-190","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Foslevodopa\/Foscarbidopa Monotherapy in Patients with Parkinson's Disease"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7441-0967","authenticated-orcid":false,"given":"Jason","family":"Aldred","sequence":"first","affiliation":[{"name":"Selkirk Neurology and Inland Northwest Research  Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Bouchard","sequence":"additional","affiliation":[{"name":"Clinique Neuro\u2010L\u00e9vis and Centre de Recherche St\u2010Louis  L\u00e9vis Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Mart\u00ednez\u2010Castrillo","sequence":"additional","affiliation":[{"name":"Department of Neurology Ram\u00f3n y Cajal University Hospital  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Soileau","sequence":"additional","affiliation":[{"name":"Texas Movement Disorder Specialists  Georgetown Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Spiegel","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resmi","family":"Gupta","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha B.","family":"Shah","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[{"name":"AbbVie Inc.  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Standaert","sequence":"additional","affiliation":[{"name":"Center for Neurodegeneration and Experimental Therapeutics University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson's Disease and Movement Disorders Center of Boca Raton  Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Henriksen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Movement Disorder Clinic University Hospital of Bispebjerg  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100010209"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26073"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70521-X"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S422717"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0220-0"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.09.001"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00782-w"},{"key":"e_1_2_9_9_1","unstructured":"DomingosJ PahwaR AntoniniA.Understanding patient perceptions of advanced Parkinson's disease (aPD) treatments. Presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS);2023."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03830-w"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S473991"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13123-y"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00351-x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00433-w"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-212612"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2009.08.053"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22112"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.12.003"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00533-1"},{"issue":"1","key":"e_1_2_9_21_1","first-page":"S23","article-title":"Open\u2010label extension study of long\u2010term safety and tolerability of foslevodopa\/foscarbidopa for treatment of advanced Parkinson's disease [abstract]","volume":"38","author":"Fung V","year":"2023","journal-title":"Mov Disord"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.7.527"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100239"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-191605"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28596"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11615-3"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70245","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:08:50Z","timestamp":1772982530000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/mdc3.70245"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70245","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"2025-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}